Aligos Therapeutics Stock Today
| ALGS Stock | USD 16.87 0.11 0.66% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Aligos Therapeutics is selling for under 16.87 as of the 1st of March 2025; that is 0.66 percent increase since the beginning of the trading day. The stock's lowest day price was 15.88. Aligos Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 30th of January 2025 and ending today, the 1st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of October 2020 | Category Healthcare | Classification Health Care |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. The company has 3.46 M outstanding shares of which 712.99 K shares are presently shorted by private and institutional investors with about 2.65 trading days to cover. More on Aligos Therapeutics
Moving together with Aligos Stock
Moving against Aligos Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Aligos Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Dr MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Alon Natural Gas Exploration Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAligos Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aligos Therapeutics' financial leverage. It provides some insight into what part of Aligos Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aligos Therapeutics (ALGS) is traded on NASDAQ Exchange in USA. It is located in One Corporate Drive, South San Francisco, CA, United States, 94080 and employs 68 people. Aligos Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 60.53 M. Aligos Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.46 M outstanding shares of which 712.99 K shares are presently shorted by private and institutional investors with about 2.65 trading days to cover.
Aligos Therapeutics currently holds about 159.34 M in cash with (79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72.
Check Aligos Therapeutics Probability Of Bankruptcy
Ownership AllocationOver half of Aligos Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions.
Check Aligos Ownership Details
Aligos Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Royal Bank Of Canada | 2024-12-31 | 23 K | |
| Drive Wealth Management, Llc | 2024-12-31 | 23 K | |
| Wells Fargo & Co | 2024-12-31 | 21.8 K | |
| Ubs Group Ag | 2024-12-31 | 15.5 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 14.3 K | |
| Blackrock Inc | 2024-12-31 | 13.7 K | |
| Renaissance Technologies Corp | 2024-12-31 | 11.4 K | |
| State Street Corp | 2024-12-31 | 9.6 K | |
| Northern Trust Corp | 2024-12-31 | 5.2 K | |
| Adage Capital Partners Gp Llc | 2024-12-31 | 325 K | |
| Ecor1 Capital, Llc | 2024-12-31 | 255.6 K |
Aligos Therapeutics Historical Income Statement
Aligos Stock Against Markets
Aligos Therapeutics Corporate Management
| TseI Lin | VP Head | Profile | |
| Leonid Beigelman | Pres Director | Profile | |
| Lucinda JD | Chief VP | Profile | |
| Matthew MD | Executive Officer | Profile | |
| Dr DABT | Executive Sciences | Profile | |
| Kristina Engeseth | Ex Culture | Profile |
Already Invested in Aligos Therapeutics?
The danger of trading Aligos Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aligos Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aligos Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aligos Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.